Use of rotigotine for the treatment of depression
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A01N-043/06
A61K-031/38
C07D-333/12
C07D-333/20
A61K-031/135
A61K-031/381
출원번호
US-0565699
(2004-07-22)
등록번호
US-8754119
(2014-06-17)
우선권정보
DE-103 34 188 (2003-07-26)
국제출원번호
PCT/EP2004/008168
(2004-07-22)
§371/§102 date
20060125
(20060125)
국제공개번호
WO2005/009424
(2005-02-03)
발명자
/ 주소
Scheller, Dieter
Breidenbach, Alexander
Selve, Norma
출원인 / 주소
UCB Pharma GmbH
대리인 / 주소
Harness, Dickey & Pierce, P.L.C.
인용정보
피인용 횟수 :
0인용 특허 :
48
초록
The present invention relates to the use of rotigotine (−)-5,6,7,8-tetrahydro-6-propyl2-(2-thienyl)ethylamino-1-naphthol and its prodrugs and pharmaceutically acceptable salts for producing a pharmaceutical agent for treating depression.
대표청구항▼
1. A method for treating depression in a mammal, comprising administering a therapeutically effective quantity of rotigotine or a metabolite, prodrug or physiologically acceptable salt thereof, to said mammal. 2. The method of claim 1, wherein the mammal is human. 3. The method of claim 2, wherein t
1. A method for treating depression in a mammal, comprising administering a therapeutically effective quantity of rotigotine or a metabolite, prodrug or physiologically acceptable salt thereof, to said mammal. 2. The method of claim 1, wherein the mammal is human. 3. The method of claim 2, wherein the depression is an endogenous depression. 4. The method of claim 3, wherein the endogenous depression is a unipolar depression or a depressive episode of a manic-depressive disorder. 5. The method of claim 2, wherein the rotigotine is administered parenterally, transdermally or mucosally. 6. The method of claim 2, wherein the rotigotine is administered in a dosage of 0.5 to about 50 mg per day. 7. The method of claim 2, wherein the rotigotine is administered in a dosage of 0.5 to 10 mg per day. 8. The method of claim 2, wherein the rotigotine is administered in a dosage of 0.5 to 5 mg per day. 9. The method of claim 1, wherein the rotigotine is administered as a prodrug thereof. 10. The method of claim 9, wherein the prodrug is an ester, carbamate, carbonate, ketal, acetate, phosphate, phosphonate, sulfate or sulfonate. 11. The method of claim 1, wherein the rotigotine is administered transdermally as rotigotine free base or hydrochloride salt. 12. The method of claim 11, wherein the rotigotine is formulated as an ointment, paste, spray, film, plaster or iontophoretic device for transdermal administration. 13. The method of claim 11, wherein the rotigotine is formulated as a plaster having the rotigotine in a matrix comprising an adhesive polymer. 14. The method of claim 11, wherein a substantially constant plasma level of rotigotine is established. 15. The method of claim 1, further comprising administering to the mammal one or more antidepressants. 16. The method of claim 1, wherein the rotigotine is administered in monotherapy. 17. The method of claim 1, wherein the quantity of rotigotine is effective for alleviation of symptoms of Parkinson's disease and for treatment of depression. 18. The method of claim 17, wherein the rotigotine is administered in monotherapy. 19. The method of claim 2, wherein the depression is a somatogenic depression. 20. The method of claim 19, wherein the somatogenic depression is an organic depression not associated with Parkinson's disease. 21. The method of claim 19, wherein the somatogenic depression is an organic depression associated with Parkinson's disease. 22. The method of claim 21, wherein co-medication with another antidepressant is absent. 23. The method of claim 20, wherein the organic depression is associated with brain tumor, migraine, epilepsy, brain paralysis, arteriosclerosis of the brain, brain trauma, meningitis, stroke, Parkinson Plus syndrome, dementia and/or cerebrovascular disease. 24. The method of claim 20, wherein the organic depression is associated with Alzheimer's disease. 25. The method of claim 19, wherein the somatogenic depression is a symptomatic depression. 26. The method of claim 25, wherein the symptomatic depression is associated with circulatory illness, hypothyroidism, hormone disorder, infectious disease, cancer and/or liver disease. 27. The method of claim 19 wherein the somatogenic depression is a pharmacogenic depression. 28. The method of claim 27, wherein the pharmacogenic depression is associated with alcohol, medication and/or drug misuse. 29. The method of claim 2, wherein the depression is a psychogenic depression. 30. The method of claim 29, wherein the psychogenic depression comprises at least one of exhaustion depression, neurotic depression and reactive depression as a result of current conflicts or events. 31. The method of claim 2, wherein the depression occurs in particular circumstances, comprising at least one of postpartum depression, old-age depression, childhood depression, seasonal depression and pubertal depression. 32. The method of claim 1, wherein the depression is associated with an affective disorder. 33. The method of claim 32, wherein the affective disorder comprises a recurrent depressive disorder and/or depressive phases in bipolar affective disorder. 34. The method of claim 2, wherein the depression manifests as depressive symptoms accompanying at least one anxiety disorder, adjustment disorder and/or organic brain disease. 35. The method of claim 2, wherein the rotigotine is administered in a dosage of 0.1 to about 50 mg per day. 36. The method of claim 2, wherein the rotigotine is administered in a dosage of 0.2 to 40 mg per day. 37. The method of claim 2, wherein the rotigotine is administered in a dosage of 0.4 to 20 mg per day. 38. The method of claim 2, wherein the rotigotine or metabolite, prodrug or salt thereof is administered in an amount effective to obtain a plasma rotigotine concentration of 0.05 to 20 ng/ml. 39. The method of claim 2, wherein the rotigotine or metabolite, prodrug or salt thereof is administered in an amount effective to obtain a plasma rotigotine concentration of 0.1 to 10 ng/ml. 40. The method of claim 2, wherein the rotigotine or metabolite, prodrug or salt thereof is administered in an amount effective to obtain a plasma rotigotine concentration of 0.2 to 5 ng/ml. 41. The method of claim 2, wherein the rotigotine or metabolite, prodrug or salt thereof is administered in an amount effective to obtain a plasma rotigotine concentration of 0.1 to 0.5 ng/ml. 42. The method of claim 9, wherein the prodrug is administered in an amount effective to obtain a plasma rotigotine concentration of 0.05 to 20 ng/ml. 43. The method of claim 42, wherein the prodrug is administered in an amount effective to obtain a plasma rotigotine concentration of 0.1 to 10 ng/ml. 44. The method of claim 42, wherein the prodrug is administered in an amount effective to obtain a plasma rotigotine concentration of 0.2 to 5 ng/ml. 45. The method of claim 42, wherein the prodrug is administered in an amount effective to obtain a plasma rotigotine concentration of 0.1 to 0.5 ng/ml. 46. The method of claim 14, wherein the rotigotine is administered in an amount effective to obtain a plasma rotigotine concentration of 0.05 to 20 ng/ml. 47. The method of claim 14, wherein the rotigotine is administered in an amount effective to obtain a plasma rotigotine concentration of 0.1 to 10 ng/ml. 48. The method of claim 14, wherein the rotigotine is administered in an amount effective to obtain a plasma rotigotine concentration of 0.2 to 5 ng/ml. 49. The method of claim 14, wherein the rotigotine is administered in an amount effective to obtain a plasma rotigotine concentration of 0.1 to 0.5 ng/ml. 50. The method of claim 15, wherein the one or more antidepressants comprise one or more serotonin reuptake inhibitors, mixed serotonin and noradrenalin reuptake inhibitors, selective noradrenaline reuptake inhibitors, monoamine oxidase inhibitors, alpha2 receptor modulators, serotonin receptor modulators, adenosine antagonists, sigma-opioid receptor ligands, NK antagonists, melatonin antagonists and/or modulators of the hypothalamus-hypophysis-adrenal axis. 51. The method of claim 50, wherein the one or more anti-depressants comprise at least one of sertaline, citalopram, partoxetine, fluoxetine, venlaxafine, milnacipram, mirtazapine, amitryptiline, imipramine, reboxetine, tranylcypramine, clorgyline, and/or nefazodone. 52. The method of claim 1, further comprising administering to the mammal one or more antipsychotics. 53. The method of claim 52, wherein the one or more antipsychotics comprise at least one of promethazine, fluphenazine, perphenazine, levomepromazine, thioridazine, perazine, promazine, chlorprothixene, zuclopenthixol, prothipendyl, flupentixol, zotepine, benperidol, pipamperon, melperon, haloperidol, bromperidol, sulpiride, clozapine, pimozide, risperidone, quetiapine, amisulpride and/or olanzapine. 54. The method of claim 1, further comprising administering to the mammal one or more sedatives. 55. The method of claim 54, wherein the one or more sedatives comprise at least one of diphenhydramine, doxylamine succinate, nitrazepam, midazolam, lormetazepam, flunitrazepam, flurazepam, oxazepam, bromazepam, triazolam, brotizolam, temazepam, chloral hydrate, zopiclone, zolpidem, tryptophan and/or zaleplon. 56. The method of claim 1, further comprising administering to the mammal one or more anxiolytics. 57. The method of claim 56, wherein the one or more anxiolytics comprise at least one of fluspirilene, thioridazine, oxazepam, alprazolam, bromazepam, lorazepam, prazepam, diazepam, clobazam, medazepam, chlordiazepoxide, dipotassium chlorazepate, nordazepam, meprobamate, buspirone, kavain and/or hydroxyzine. 58. The method of claim 1, further comprising administering to the mammal one or more anti-migraine agents. 59. The method of claim 58, wherein the one or more anti-migraine agents comprise at least one of almotriptan, zolmitriptan, acetylsalicylic acid, ergotamine, dihydroergotamine, methysergide, iprazochrome, ibuprofen, sumatriptan, rizatriptan, naratriptan and/or paracetamol. 60. The method of claim 1, further comprising administering to the mammal at least one additional active ingredient comprising one or more antidepressants, antipsychotics, sedatives, anxiolytics and/or anti-migraine agents, wherein the rotigotine or metabolite, prodrug or salt thereof and the at least one additional active ingredient are provided in separate dosage forms for administration by the same or different routes at the same or different times. 61. The method of claim 1, further comprising administering to the mammal at least one additional active ingredient comprising one or more antidepressants, antipsychotics, sedatives, anxiolytics and/or anti-migraine agents, wherein the rotigotine or metabolite, prodrug or salt thereof and the at least one additional active ingredient are administered in a single dosage form. 62. A method for treating endogenous depression in a mammal, comprising administering a therapeutically effective quantity of rotigotine or a metabolite, prodrug or physiologically acceptable salt thereof, to said mammal.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (48)
Huth Andreas (Berlin DEX) Sauer Gerhard (Berlin DEX) Wachtel Helmut (Berlin DEX), 1,2-disubstituted ergolines useful for producing central antidopanminergic or a
상세보기
Thurkauf Andrew (Branford CT) Hutchison Alan (Madison CT), 4-aryl substituted piperazinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype specific liga.
Welch, Jr., Willard M.; Harbert, Charles A.; Koe, B. Kenneth; Kraska, Allen R., Antidepressant derivatives of trans-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine.
Lin Chiu-Hong (Portage MI) Haadsma-Svensson Susanne R. (Gothenburg MI SEX) McCall Robert B. (Kalamazoo MI) Romero Arthur G. (Kalamazoo MI) Darlington William H. (Kalamazoo MI) Ennis Michael D. (Porta, Carboxamido-(1,2N)-carbocyclic-2-aminotetralin derivatives.
Svensson Kjell A. I. (Goteborg SEX) Wikstrom Hakan V. (Groningen SEX) Carlsson Per A. E. (Goteborg SEX) Boije Anna M. P. (Lerum SEX) Waters R. Nicholas (Goteborg SEX) Sonesson Clas A. (Goteborg SEX) , Centrally acting substituted phenylazacycloalkanes.
Thurkauf Andrew (Branford CT) Hutchison Alan (Madison CT), Certain aminomethyl phenylimidazole derivatives; and 4-aryl substituted piperazinyl and piperidinylmethyl phenylimidazol.
Rimpler,Stephan; Grapatin,Sabine; Krein,Cliff; Thelen,Markus, Injectable pharmaceutical composition for systematic administration of pharmacologically active ingredients.
Patel Dinesh C. (Murray UT) Chang Yunik (Lakewood NJ), Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols.
Hoffmann Hans R. (Neuwied DEX) Meconi Reinhold (Neuwied DEX) Wolff Michael (Monheim DEX) Zerbe Horst (Monheim DEX), Pharmaceutical product, in medical bandage form.
Peglion Jean L. (Le Vesinet FRX) Poignant Jean C. (Bures sur Yvette FRX) Vian Joel (Chaville FRX), Pharmacologically active amino-5,6,7,8-tetrahydronaphtho [2,3-B]furan compounds.
Chen Tung-Fen ; Chiang Chia-Ming ; Jona Janan ; Joshi Priti ; Ramdas Asha, Polyurethane hydrogel drug reservoirs for use in transdermal drug delivery systems, and associated methods of manufactu.
Sylvia Rossi-Montero ; Juan Mantelle ; David Kanios ; David Houze, Solubility enhancement of drugs in transdermal drug delivery systems and methods of use.
Miranda Jesus (Miami FL) Sablotsky Steven (Miami FL), Solubility parameter based drug delivery system and method for altering drug saturation concentration.
Horn ; deceased Alan S. (late of Noordhorn IL NLX by Mark Horn ; legal representative) Dubocovich Margarita L. (Evanston IL), Substituted 2-amidotetralins as melatonin agonists and antagonists.
Karen L. Marquis, Therapeutic combinations of (S)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro 7H-1,4-dioxino{2,3-e}indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders.
Lin Chiu-Hong (Portage MI) Haadsma-Svensson Susanne R. (Portage MI) Piercey Montford F. (Kalamazoo MI) Romero Arthur G. (Kalamazoo MI) Darlington William H. (Kalamazoo MI), Therapeutically useful 2-aminotetralin derivatives.
Andersson Bengt R. (Lindome SEX) Carlsson Per Arvid E. (Goteborg SEX) Svensson Kjell A. I. (Alingas SEX) Wikstrom Hakan V. (Partille SEX), Therapeutically useful tetralin derivatives.
Nichols Cynthia L. (Indianapolis IN) Kornfeld Edmund C. (Indianapolis IN), Trans-(±)-2,4,6-substituted-5,5a,6,7,8,9,9a,10-octahydro-pyrimido[4,5-g]quinolines.
Muller, Walter; Peck, James V., Transdermal therapeutic system which contains a d2 agonist and which is provided for treating parkinsonism, and a method for the production thereof.
Oertel Wolfgang H.,DEX ; Meier Dieter,DEX ; Gomez-Mancilla Baltazar ; Montplaisir Jacques,CAX, Use of pramipexole in the treatment of restless legs syndrome.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.